The estimated Net Worth of Nathaniel E David is at least $11.4 Million dollars as of 16 December 2020. Nathaniel David owns over 1,700,000 units of Unity Biotechnology Inc stock worth over $874,584 and over the last 6 years he sold UBX stock worth over $8,908,000. In addition, he makes $1,611,100 as President, Co-Founder und Director at Unity Biotechnology Inc.
Sign up
Nathaniel David UBX stock SEC Form 4 insiders trading
Nathaniel has made over 2 trades of the Unity Biotechnology Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 1,700,000 units of UBX stock worth $8,908,000 on 16 December 2020.
The largest trade he's ever made was selling 1,700,000 units of Unity Biotechnology Inc stock on 16 December 2020 worth over $8,908,000. On average, Nathaniel trades about 131,015 units every 15 days since 2018. As of 16 December 2020 he still owns at least 624,703 units of Unity Biotechnology Inc stock.
You can see the complete history of Nathaniel David stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Nathaniel David biography
Dr. Nathaniel E. David is President, Co-Founder, Director of the company. He is our co-founder and has served as a member of our board of directors since its inception in November 2011, our President since January 2016, and as our Chief Executive Officer from our inception until January 2016. Dr. David was a co-founder of and served as Chief Science Officer of KYTHERA from January 2005 to September 2009 and a member of the board of directors from its inception until its acquisition by Allergan. He was a co-founder of Syrrx, Inc., a biotechnology company, or Syrrx, which was acquired by Takeda Pharmaceutical Company Limited, a public pharmaceutical company, or Takeda, where he was Director of Business Development from 1999 to 2003. Dr. David was also a co-founder of Achaogen, Inc., a public biotechnology company, and Sapphire Energy, Inc., an energy company. Dr. David currently serves on the board of trustees of the University of California Foundation. Dr. David previously served on the board of trustees of the Buck Institute for Research on Aging, and on the board of directors of Sapphire Energy, Inc. Dr. David received an B.A. in Biology from Harvard University and a Ph.D. in Molecular and Cellular Biology from the University of California, Berkeley. David is qualified to serve on our board of directors due to his extensive scientific and operational background gained as a research scientist, founder, and executive focused on life science and pharmaceutical companies.
What is the salary of Nathaniel David?
As the President, Co-Founder und Director of Unity Biotechnology Inc, the total compensation of Nathaniel David at Unity Biotechnology Inc is $1,611,100. There are 2 executives at Unity Biotechnology Inc getting paid more, with Keith Leonard having the highest compensation of $3,270,820.
How old is Nathaniel David?
Nathaniel David is 52, he's been the President, Co-Founder und Director of Unity Biotechnology Inc since 2016. There are 15 older and 6 younger executives at Unity Biotechnology Inc. The oldest executive at Unity Biotechnology Inc is David Lacey, 67, who is the Independent Director.
What's Nathaniel David's mailing address?
Nathaniel's mailing address filed with the SEC is C/O UNITY BIOTECHNOLOGY, INC., 285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Unity Biotechnology Inc
Over the last 6 years, insiders at Unity Biotechnology Inc have traded over $9,012,473 worth of Unity Biotechnology Inc stock and bought 3,200 units worth $28,480 . The most active insiders traders include Kristina Burow, Robert Nelsen und Nathaniel E David. On average, Unity Biotechnology Inc executives and independent directors trade stock every 54 days with the average trade being worth of $65,316. The most recent stock trade was executed by Alexander Hieu Nguyen on 2 August 2024, trading 154 units of UBX stock currently worth $236.
What does Unity Biotechnology Inc do?
unity biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. unity's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. more information is available at www.unitybiotechnology.com.
What does Unity Biotechnology Inc's logo look like?
Complete history of Nathaniel David stock trades at Unity Biotechnology Inc
Unity Biotechnology Inc executives and stock owners
Unity Biotechnology Inc executives and other stock owners filed with the SEC include:
-
Keith Leonard,
Chairman of the Board -
Margo Roberts,
Independent Director -
Nathaniel David,
President, Co-Founder, Director -
Dr. Anirvan Ghosh,
CEO & Director -
Dr. Jamie Dananberg M.D.,
Chief Medical Officer -
Dr. Jamie Dananberg,
Chief Medical Officer -
Lynne Marie Sullivan,
CFO & Head of Corp. Devel. -
Paul Berns,
Independent Director -
Graham Cooper,
Independent Director -
David Lacey,
Independent Director -
Kristina Burow,
Independent Director -
Camille Samuels,
Independent Director -
Robert Nelsen,
Director -
Dr. Nathaniel E. David A.B., Ph.D.,
Co-Founder & Exec. Director -
Luis Visoso,
Director -
Mary Campbell,
Director -
Jamie Dananberg,
Chief Medical Officer -
Tamara Tompkins,
General Counsel and Corporate Secretary -
Dan Marquess,
Chief Scientific Officer -
Lynne Sullivan,
Chief Financial Officer, Chief Accounting Officer -
Anirvan Ghosh,
Chief Executive Officer, Director -
Dr. Nathaniel E. David,
Co-Founder & Exec. Director -
Susan Lundeen Smuck,
Chief HR Officer -
Dr. Przemyslaw Sapieha Ph.D.,
Chief Scientific Advisor -
Alexander Azoy,
VP of Fin., Chief Accounting Officer, Controller & Principal Accounting Officer -
Nathan Guz Ph.D.,
VP of Operations -
Daohong Zhou M.D.,
Founder -
Dr. Judith Campisi,
Founder -
Dr. Jan M. van Deursen,
Founder -
Alexander Azoy,
See Remarks -
Alexander Hieu Nguyen,
Chief Legal Officer -
Ii Robert C. Goeltz,
Chief Financial Officer -
Venture Partners Vii, Llcar...,
-
Michael P. Samar,
-
Gilmore Neil O'neill,